A Phase 3 interventional study of Ruxolitinib and Hydroxyurea (HU) in Polycythemia Vera, sponsored by Incyte Corporation. Completed at 70 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-14.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing ruxolitinib in Polycythemia Vera — 5 open to participants now, 8 under way, 1 of them phase 3. ruxolitinib · Polycythemia Vera.
Among the 17 studies testing ruxolitinib in Polycythemia Vera, this one is the 9th largest by enrollment, is the only one that started in 2012, is one of 5 in phase 3, and was the 5th registered.
279 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.
Browse Polycythemia Vera studies →5 of the 17 studies testing ruxolitinib in Polycythemia Vera are open now, in 3 countries. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
University of Birmingham · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 5 · Phase 4 1
First in 2007; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 52 across 205 interventional studies indexed under Polycythemia Vera.
Median enrollment 110 across the 17 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 17 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Incyte Corporation has 6 studies filed under Polycythemia Vera — fewer than ten, so there is no comparison to draw.
4 of the studies testing ruxolitinib in Polycythemia Vera that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT04644211Massachusetts General HospitalRuxolitinib in Thrombocythemia and Polycythemia Vera | 2027-07 |
| NCT04282187University of WashingtonDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | 2027-11-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies testing ruxolitinib in Polycythemia Vera, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the RELIEF study is to compare symptoms in polycythemia vera (PV) subjects treated with ruxolitinib versus subjects treated with hydroxyurea (HU) as measured by the percent of subjects who achieve a clinically meaningful symptom improvement (ie, total symptom score reduction of ≥ 50% reduction) at Week 16 compared to Baseline. The study is also designed to demonstrate that these responses are durable with continued treatment.
This is a Phase 3 multicenter, double-blind, double-dummy, randomized study. Only subjects with PV who have received HU for at least 12 weeks, have been receiving a stable dose before screening, and still have symptoms related to PV will be enrolled.
Subjects will be randomized (1:1) to 1 of 2 treatment arms:
A: ruxolitinib and HU-placebo B: HU and ruxolitinib-placebo
Subjects randomized to either arm may be eligible to transition to open-label ruxolitinib after Week 16.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects should meet at least 1 of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ruxolitinib · Drug: HU-placebo
Drug: Hydroxyurea (HU) · Drug: Ruxolitinib-placebo
Ruxolitinib will be orally self-administered at a starting dose of 10 mg (two 5 mg tablets) twice a day. Dose increases of 5 mg (1 tablet) in twice-daily increments are permitted after 4 weeks and again after 8 weeks of therapy for subjects who meet prespecified criteria for inadequate efficacy.
Hydroxyurea (500 mg capsules) will be orally self-administered at the dose that the subject was receiving previously. The dose may be increased after 4 weeks and again after 8 weeks of therapy to optimize efficacy for subjects meeting prespecified criteria.
All placebo will be self-administered, and dosing will be the same as with the blinded dose. When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently.
All placebo will be self-administered, and dosing will be the same as with the blinded dose. When adjustments are made to the HU dose, the dose of ruxolitinib-placebo will be adjusted concurrently.
Percentage of Subjects Achieving a ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine (TSS-C) at Week 16, as Measured by the Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Diary
Symptoms of polycythemia vera were assessed using a modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) electronic diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): tiredness, itching, muscle aches, night sweats, and sweats while awake. The total symptom score ranged from 0-50 and was calculated as the sum of the 5 symptom scores. A higher score indicates worse symptoms.
Time frame: From Baseline to Week 16
Percentage of Subjects Achieving ≥ 50% Improvement From Baseline in the Individual Symptom Scores for TSS-C at Week 16
The TSS-C cluster includes tiredness, itching, muscle aches, night sweats, and sweats while awake.
Time frame: From Baseline to Week 16
Proportion of Subjects Randomized to Ruxolitinib Who Achieved ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine and the Individual Symptom Scores at Week 16 That Were Maintained at Week 48
Durable Response on TSS-C/individual symptoms defined as a ≥ 50% reduction in TSS-C/individual symptoms at Week 16 that were maintained at Week 48
Time frame: Week 48
| Milestone | Ruxolitinib | Hydroxyurea |
|---|---|---|
| Started | 54 | 56 |
| Completed | 47 | 50 |
| Not completed | 7 | 6 |
| Withdrew: Adverse event | 4 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Subject decision | 3 | 2 |
| Withdrew: Disease progression | 0 | 1 |
| Withdrew: Reason for discontinuation not available | 0 | 1 |
Symptoms of polycythemia vera were assessed using a modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) electronic diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): tiredness, itching, muscle aches, night sweats, and sweats while awake. The total symptom score ranged from 0-50 and was calculated as the sum of the 5 symptom scores. A higher score indicates worse symptoms.
| Percentage of participants | Ruxolitinib | Hydroxyurea |
|---|---|---|
| Percentage of Subjects Achieving a ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine (TSS-C) at Week 16, as Measured by the Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Diary | 43.4 | 29.6 |
The TSS-C cluster includes tiredness, itching, muscle aches, night sweats, and sweats while awake.
| Percentage of participants | Ruxolitinib | Hydroxyurea |
|---|---|---|
| Tiredness (n= 50, 53) | 40.0 | 26.4 |
| Itching (n= 48, 50) | 54.2 | 32.0 |
| Muscle aches (n= 47, 49) | 38.3 | 30.6 |
| Night sweats (n= 42, 48) | 47.6 | 41.7 |
| Sweats while awake (n= 42, 46) | 54.8 | 34.8 |
Durable Response on TSS-C/individual symptoms defined as a ≥ 50% reduction in TSS-C/individual symptoms at Week 16 that were maintained at Week 48
| percentage of participants | Ruxolitinib |
|---|---|
| TSS-C | 31.5 (19.5 to 45.6) |
| Tiredness | 24.1 (13.5 to 37.6) |
| Itching | 37.0 (24.3 to 51.3) |
| Muscle aches | 20.4 (10.6 to 33.5) |
| Night sweats | 29.6 (18.0 to 43.6) |
| Sweats while awake | 37.0 (24.3 to 51.3) |
Collected over The duration of the study up to Week 16. This time frame defines the blinded, comparative phase of the study where the majority of patients remained on their original randomized assignment and exposure between ruxolitinib and hydroxyurea was similar.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib | — | 5/54 (9.3%) | 50/54 (92.6%) |
| Hydroxyurea | — | 4/56 (7.1%) | 45/56 (80.4%) |
| Event | Ruxolitinib | Hydroxyurea |
|---|---|---|
| Angina unstableCardiac disorders | 1/54 | 0/56 |
| Arterial occlusive diseaseVascular disorders | 1/54 | 0/56 |
| Cerebral ischemiaNervous system disorders | 1/54 | 0/56 |
| Chest discomfortGeneral disorders | 1/54 | 0/56 |
| Platelet count increasedInvestigations | 1/54 | 0/56 |
| SpondylolisthesisMusculoskeletal and connective tissue disorders | 1/54 | 0/56 |
| Deep vein thrombosisVascular disorders | 0/54 | 1/56 |
| HematuriaRenal and urinary disorders | 0/54 | 1/56 |
| Hemoglobin decreasedInvestigations | 0/54 | 1/56 |
| HydronephrosisRenal and urinary disorders | 0/54 | 1/56 |
| Event | Ruxolitinib | Hydroxyurea |
|---|---|---|
| FatigueGeneral disorders | 11/54 | 6/56 |
| DiarrheaGastrointestinal disorders | 5/54 | 11/56 |
| HeadacheNervous system disorders | 9/54 | 3/56 |
| AnemiaBlood and lymphatic system disorders | 8/54 | 5/56 |
| DizzinessNervous system disorders | 7/54 | 5/56 |
| ConstipationGastrointestinal disorders | 4/54 | 7/56 |
| RashSkin and subcutaneous tissue disorders | 6/54 | 0/56 |
| NauseaGastrointestinal disorders | 6/54 | 3/56 |
| PruritusSkin and subcutaneous tissue disorders | 6/54 | 6/56 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/54 | 5/56 |
| Age, Continuous(years) | Ruxolitinib | Hydroxyurea | Total |
|---|---|---|---|
| Mean | 63.1 ± 11.68 | 64.2 ± 12.68 | 63.7 ± 12.15 |
| Sex: Female, Male(Participants) | Ruxolitinib | Hydroxyurea | Total |
|---|---|---|---|
| Female | 30 | 22 | 52 |
| Male | 24 | 34 | 58 |
| Race/Ethnicity, Customized(participants) | Ruxolitinib | Hydroxyurea | Total |
|---|---|---|---|
| White or Caucasian | 53 | 56 | 109 |
| Asian | 1 | 0 | 1 |
The record gives a start of Jun 2012, a primary completion of Mar 2014 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 1 month after primary completion. A results delay was requested in Apr 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib